We use cookies to make sure that our website works properly, as well as some ‘optional’ cookies to personalise content and advertising, provide social media features and analyse how people use our site. Further information can be found in our Cookies policy
The Biopharmaceutics Classification System (BCS) is a scientifically established framework introduced by the U.S. FDA to categorize drug substances according to their solubility and permeability properties. This system plays a vital role in drug development, especially for generic drugs, by enabling the prediction of in vivo drug performance using in vitro data. By classifying drugs into four categories (Class I to IV), the BCS helps identify potential bioavailability challenges and supports the design of effective formulation strategies.The current review aims on solubility issues and the modern techniques to enhance and improve solubility by studying various aspects...
(1)The Biopharmaceutical Classification System (BCS) is a sophisticated framework designed to categorize drug substances based on their dissolution properties, intestinal permeability, and water solubility. In 1995, Amidon et al. introduced a theoretical approach to correlate in vitro drug dissolution with in vivo bioavailability, marking a significant advancement in pharmaceutical science.(2) The BCS serves as a valuable tool in drug development, aiding in the efficient management of drug discovery and the early stages of developing new medications. This system has become an essential component in optimizing pharmaceutical formulations and predicting drug performance. The oral route is the most favored and extensively utilized method for drug administration, playing a central role in drug delivery technologies. However, despite its widespread use, this route faces significant challenges related to absorption and bioavailability within the gastrointestinal (GI) environment. When an oral dosage form is administered, the drug must first be released and dissolved in the GI fluids to form a solution. This step is often limited by the drug's solubility, which can hinder its effectiveness. Once dissolved, the drug must then permeate through the cell membranes lining the GI tract, a process that depends on the drug's permeability. These two factors—solubility and permeability—are critical in determining the overall bioavailability and therapeutic efficacy of orally administered drugs. Overcoming these challenges is vital for optimizing drug delivery and ensuring successful treatment outcomes.
Key Concepts of the BCS
Solubility:
Solubility refers to the ability of a drug to dissolve in aqueous media (e.g., water) across a physiological pH range (1.2–7.5).
A drug is considered highly soluble if the highest dose strength dissolves in ≤ 250 mL of water within the pH range.
Poor solubility is a major challenge in drug development, as it can limit bioavailability and therapeutic efficacy.
Permeability:
Permeability refers to the ability of a drug to cross biological membranes, such as the intestinal epithelium.
A drug is considered highly permeable if ≥ 90% of the administered dose is absorbed.
Low permeability can also limit bioavailability, as the drug may not reach systemic circulation in sufficient quantities.
BCS Classes:
(3)The BCS categorizes drugs into four classes based on solubility and permeability:
Class I: High Solubility, High Permeability
These drugs are well-absorbed and exhibit high bioavailability.
Example: Metoprolol, Propranolol.
Solubility and permeability are not limiting factors for Class I drugs.
Class II: Low Solubility, High Permeability
These drugs have poor solubility but good permeability.
Solubility is the limiting factor for absorption, often leading to bioavailability issues.
Example: Naproxen, Phenytoin.
Formulation strategies (e.g., nanosuspensions, solid dispersions, lipid-based formulations) are often required to enhance solubility.
Class III: High Solubility, Low Permeability
These drugs dissolve well but struggle to cross biological membranes.
Permeability is the limiting factor for absorption.
Example: Atenolol, Metformin.
Strategies to enhance permeability (e.g., permeation enhancers) are often employed.
Class IV: Low Solubility, Low Permeability
These drugs face challenges with both solubility and permeability.
They often have poor bioavailability and require advanced formulation strategies.
Example: Taxol, Amphotericin B
Nanotechnology, prodrugs, and targeted delivery systems are often explored for Class IV drugs.
Table 1: BCS Classification System.
Table 2: Techniques for Solubility enhancement
FORMULATION TECHNIQUES:
Particle Size Reduction
(4)This involves reducing the size of drug particles to improve their dissolution rate, bioavailability, and overall effectiveness.
Purpose: Smaller particles have a larger surface area, which enhances solubility and absorption, especially for poorly water-soluble drugs.
(5)Methods:
Milling: Mechanical grinding to reduce particle size.
Micronization: Produces particles in the micrometer range.
Nanoparticle formation: Produces particles in the nanometer range.
Applications: Used in oral, injectable, and inhalable drug formulations.
Solid Dispersion
(6)A technique where a drug is dispersed in a solid, inert carrier (e.g., polymers) to improve its solubility and dissolution rate.
Improving the solubility of drugs with low water solubility can be effectively achieved through various solid dispersion techniques. Some of the key approaches include:
1. Hydrotropy and Mixed Hydrotropy-Based Solid Dispersion Techniques:
(7) These methods involve the use of a combination of hydrotropic agents during the preparation of solid dispersions via solvent evaporation. Hydrotropic agents help increase the solubility of drugs in water, thereby improving their dissolution rates.
2. Dispersion in an Inert Hydrophilic Carrier:
This technique involves dispersing poorly water-soluble drug molecules into an inert hydrophilic carrier. The hydrophilic nature of the carrier improves the drug's dissolution characteristics, leading to enhanced bioavailability.
3. Solid Dispersion and Pelletization Methods:
(8) Solid dispersions can be prepared using solvent evaporation techniques, where the drug is dispersed in a polymer matrix to improve solubility. Additionally, pelletization involves coating the drug onto nonpareil sugar beads to form pellets.
Purposes of Solid dispersion techniques: Enhances the bioavailability of poorly water-soluble drugs by converting them into amorphous or molecularly dispersed states.
Methods:
Hot-melt extrusion: Mixing drug and carrier at high temperatures.
Solvent evaporation: Dissolving drug and carrier in a solvent, followed by solvent removal.
Applications: Commonly used for oral drug delivery.
Micro and Nano Emulsion
(9)Emulsions are mixtures of two immiscible liquids (oil and water) stabilized by surfactants. Microemulsions are thermodynamically stable, transparent systems with droplet sizes in the nanometer range, while nanoemulsions are kinetically stable with droplet sizes in the nanometer to micrometer range.
Micro and Nanoemulsions enhance the permeability of drug particles through skin particularly in transdermal gel formulations,their ability to improve drug absorption can lead to a faster onset action and enhanced therapeutic actions.
Purpose: Improves the solubility and bioavailability of lipophilic drugs and enables targeted drug delivery.
Components:
Oil phase: Dissolves lipophilic drugs.
Aqueous phase: Dissolves hydrophilic drugs.
Surfactants and co-surfactants: Stabilize the emulsion.
Applications: Used in oral, topical, and injectable formulations.
Porous Tablet Formation
(10)A technique to create tablets with a porous structure, which enhances drug dissolution and absorption.
Purpose: Improves the disintegration and dissolution rate of tablets, especially for poorly soluble drugs.
Methods:
Freeze-drying (lyophilization): Creates a highly porous structure.
Use of pore-forming agents: Agents that dissolve or evaporate during manufacturing, leaving behind pores.
Applications: Fast-dissolving tablets and controlled-release formulations
Lipid-Based Formulation
(13)Drug delivery systems that use lipids (fats or oils) as carriers to improve the solubility and bioavailability of poorly water-soluble drugs.
Lipid-based formulations provide a promising solution for enhancing the solubility and bioavailability of poorly water-soluble drugs. Techniques such as lipid-based drug delivery systems (LBDDS) and lipid-based prodrugs can effectively solubilize drugs, prevent their precipitation, and improve absorption. (14)This ultimately leads to better therapeutic outcomes and increased efficacy of the drug.
Purpose: Enhances drug absorption by solubilizing the drug in lipid matrices or emulsions.
Types:
Lipid solutions: Drug dissolved in oils.
Lipid emulsions: Oil-in-water or water-in-oil emulsions.
Self-emulsifying drug delivery systems (SEDDS): Formulations that form emulsions upon contact with water.
Applications: Oral, parenteral, and topical drug delivery.
Surfactant and Cosolvents
(11)Surfactants and co-solvents are widely used in pharmaceutical formulations to improve the dissolution rate of drugs with poor water solubility. Such drugs often struggle with inadequate and inconsistent oral absorption due to their limited ability to dissolve in water. Surfactants function by reducing the surface tension between the drug and the surrounding medium, facilitating the drug's release into the dissolution medium. This approach helps enhance bioavailability and ensures more consistent therapeutic effects.
(12)Surfactants: Amphiphilic molecules that reduce surface tension and improve drug solubility by forming micelles.
Cosolvents: Water-miscible solvents (e.g., ethanol, propylene glycol) used to enhance drug solubility.
Purpose: Improve the solubility and stability of poorly water-soluble drugs.
Mechanism:
Surfactants form micelles that encapsulate hydrophobic drugs.
Cosolvents alter the polarity of the solvent system to dissolve drugs.
Applications: Used in oral, injectable, and topical formulations.
STRUCTURAL ENGINEERING:
Salt Formation
(15)The process of converting a drug into its salt form by reacting it with an acid or base. This alters the drug's physicochemical properties without changing its therapeutic activity.
Salt formation is a widely used and effective strategy to enhance the solubility of poorly water-soluble drugs. By converting a drug into its salt form, its physicochemical properties are modified, often leading to improved water solubility and bioavailability. Below is a detailed explanation of this approach, including its applications and key considerations
Factors Influencing Salt Formation:
pKa of the drug and counterion: The difference in pKa values (ΔpKa) between the drug and counterion plays a crucial role in determining the formation of a salt or cocrystal.
pH: The pH of the medium significantly impacts the solubility and dissolution of salts.
Solubility Product (Ksp): The Ksp value, which reflects the solubility of the salt, is another important factor
Purpose:
Improve solubility and dissolution rate.
Enhance bioavailability.
Modify stability and shelf life.
Adjust taste or reduce irritation.
Mechanism:
Acidic drugs form salts with bases (e.g., sodium, potassium).
Basic drugs form salts with acids (e.g., hydrochloride, sulfate).
Morphine (basic drug) → Morphine sulfate (improved stability and solubility).
Applications: Widely used in oral, injectable, and topical formulations.
Drug Complexation
(16)The formation of a complex between a drug molecule and another molecule (e.g., cyclodextrins, polymers) to improve its physicochemical properties.
Cyclodextrins, including α-, β-, and γ-cyclodextrins, are widely used for complexation to improve the solubility and dissolution of poorly water-soluble drugs.(17) Among these, β-cyclodextrin is particularly favored due to its optimal cavity size and hydrophilic properties. Modified cyclodextrins, such as sulfobutyl ether β-cyclodextrin (Captisol), are also employed to further enhance solubility and dissolution rates. The choice of complexation method depends on several factors, including the drug's solubility, compatibility with cyclodextrins, and the desired properties of the resulting complex. (18)Characterization of these complexes is typically performed using techniques like differential scanning calorimetry (DSC), infrared spectroscopy, X-ray diffractometry, and near-infrared spectroscopy.
Purpose:
Enhance solubility and stability.
Mask unpleasant taste or odor.
Control drug release.
Mechanism:
The drug molecule fits into the cavity of a complexing agent (e.g., cyclodextrins) through non-covalent interactions (e.g., hydrogen bonding, van der Waals forces).
Examples:
Cyclodextrin complexes: Used to solubilize hydrophobic drugs like ibuprofen.
Ion-exchange resins: Used to control drug release (e.g., dextromethorphan resin complex for sustained release).
Applications: Oral, topical, and controlled-release formulations.
Prodrug
(19)A biologically inactive compound that is converted into an active drug within the body through enzymatic or chemical processes.
Types of Prodrugs:
(20)Carrier-Linked Prodrugs: The active drug is linked to a carrier moiety (e.g., ester, amide) that is cleaved enzymatically or chemically in the body.
Example: Valacyclovir (prodrug of acyclovir) for improved oral bioavailability.
Bioprecursor Prodrugs: The prodrug undergoes molecular modification (e.g., oxidation, reduction) to release the active drug.
Example: Levodopa (prodrug of dopamine) for Parkinson’s disease.
(21)Mutual Prodrugs: Two pharmacologically active drugs are linked together, each acting as a carrier for the other.
Example: Sulfasalazine (used in inflammatory bowel disease).
Purpose:
Improve solubility, absorption, and bioavailability.
Enhance stability and reduce side effects.
Enable targeted drug delivery.
Mechanism:
Prodrugs are designed to overcome barriers (e.g., poor solubility, instability, or toxicity) by modifying the drug's structure.
Once administered, the prodrug is metabolized (e.g., hydrolyzed, oxidized) to release the active drug.
Examples:
Enalapril (prodrug) → Enalaprilat (active drug for hypertension).
Levodopa (prodrug) → Dopamine (active drug for Parkinson’s disease).
Applications: Used in oral, injectable, and targeted drug delivery systems.
(22)Brief summary of formulation techniques
SR.NO.
TECHNIQUE
PURPOSE
APPLICATIONS
1.
Particle size Reduction
Improve solubility and bioavailability
Oral, Injectable, Inhalable drugs
2.
Solid Dispersion
Enhance solubility and dissolution of poorly soluble drugs
Oral drug delivery
3.
Micro and Nano Emulsion
Improve solubility and enable targeted delivery
Oral, topical, injectable formulations
4.
Porous Tablet Formation
Increase disintegration and dissolution of tablets
Fast dissolving and control release tablets
5.
Lipid Base Formulation
Improve solubility and bioavailability of lipophilic drugs
Oral, parentral, topical delivery
6.
Surfactant and Co-solvents
Enhance solubility and stability of poorly soluble drugs
Topical, injectable, oral formulations
(23)Brief formulation of structural engineering techniques
Sr.No
Technique
Purpose
Mechanism
Examples
1
Salt formation
Improve solubility, stability and bioavailability
Reaction of drug with acids/base to form ionic salt
Morphine sulphate, sodium salicylate.
2
Drug complexation
Enhance solubility and control release
Non-co-valent interaction with complexing agents Ex: cyclodextrins.
Ibuprofen-cyclodextrine complex.
3
Prodrug
Improve solubility and reduce side effects
Inactive form metabolized to active drug in the body
Enalapril, levodopa.
RELEVANCE OF THE BCS TO SOLUBILITY ISSUES
(24)Predicting Bioavailability:
The BCS helps predict the bioavailability of a drug based on its solubility and permeability. Poor solubility is a major cause of low bioavailability, particularly for Class II and IV drugs.
Formulation Development:
(25)The BCS guides formulation scientists in selecting appropriate strategies to overcome solubility issues. For example:
Class II drugs: Solubility-enhancing techniques like micronization, solid dispersions, and lipid-based formulations are commonly used.
Class IV drugs: Advanced delivery systems, such as nanoparticles and liposomes, are often explored.
Regulatory Implications:
The BCS is used by regulatory agencies to grant *biowaivers* for certain drugs, particularly Class I and III drugs, which do not require in vivo bioequivalence studies if they meet specific criteria.
This reduces the time and cost of drug development, especially for generic drugs.
Drug Discovery and Development:
The BCS is used early in drug discovery to screen compounds for solubility and permeability issues. This helps identify potential challenges and optimize lead compounds.
CHALLENGES AND LIMITATIONS OF THE BCS(26,27)
Dynamic Nature of Solubility:
Solubility can vary with pH, temperature, and the presence of excipients, which may not always be accounted for in the BCS framework.
Permeability Variability:
Permeability can be influenced by factors such as efflux transporters, metabolism, and regional differences in the GI tract, which are not fully addressed by the BCS.
Limited Applicability to Complex Formulations:
The BCS may not fully predict the performance of complex formulations, such as modified-release products or those using advanced delivery systems.
Class IV Drugs:
Class IV drugs pose significant challenges due to their poor solubility and permeability, often requiring innovative formulation strategies that go beyond the BCS framework.
RECENT ADVANCES AND FUTURE DIRECTIONS(28)
BCS-Based Biowaivers:
Regulatory agencies are expanding the use of BCS-based biowaivers to include more drugs, particularly Class III drugs, to expedite generic drug approvals.
BCS Beyond Oral Drugs:
The BCS framework is being adapted for other routes of administration, such as transdermal and parenteral delivery, to address solubility and permeability issues in these contexts.
Computational Tools:
Advances in computational modeling and artificial intelligence are being used to predict solubility and permeability more accurately, aiding in drug development and BCS classification.
Nanotechnology and Novel Delivery Systems:
Nanotechnology-based approaches, such as nanoparticles, liposomes, and micelles, are being explored to enhance solubility and bioavailability, particularly for Class II and IV drugs.
CONCLUSION
The Biopharmaceutics Classification System (BCS) is a valuable tool for understanding and addressing solubility and permeability issues in drug development. It provides a systematic framework for predicting bioavailability, guiding formulation strategies, and streamlining regulatory processes. However, the BCS has limitations, particularly for Class IV drugs and complex formulations. Ongoing research and technological advancements are expanding the applicability of the BCS and improving its predictive power, making it an indispensable tool in modern pharmaceutical science. Enhancing solubility and dissolution rates is a critical focus in pharmaceutical development, especially for drugs classified as BCS Class II. These drugs, which exhibit poor solubility but high permeability, pose significant challenges in formulation and delivery, often limiting their bioavailability and therapeutic effectiveness. To address these issues, various strategies have been employed, including solid dispersion, cyclodextrin complexation, nanoparticle formulation, and particle size reduction. These approaches have demonstrated significant potential in improving drug solubility, dissolution kinetics, and pharmacokinetic profiles, thereby contributing to better patient outcomes.
REFERENCES
Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-420.
Reddy BBK, Karunakar A. Biopharmaceutics classification system: a regulatory approach. Dissolution Technol. 2011;18:31-37
Emami J, “In vitro - in vivo correlation: From theory to applications,” J. Pharm. Pharmaceut. Sci., 2006; 9(2): 169-189
Kumar R, Thakur AK, Chaudhari P, Banerjee N. Particle size reduction techniques of pharmaceutical compounds for the enhancement of their dissolution rate and bioavailability. Journal of Pharmaceutical Innovation. 2022 Jun;17(2):333-52.
Martena V, Shegokar R, Di Martino P, Müller RH. Effect of four different size reduction methods on the particle size, solubility enhancement and physical stability of nicergoline nanocrystals.
Kunam VI, Garikapati DR, Suryadevara VI, Mandava VB, Janga RB, Sunkara SP. Solubility and dissolution rate enhancement of telmisartan by solid dispersion and pelletization techniques using soluplus as carrier. International Journal of Applied Pharmaceutics. 2020;12(1):50-8
Ali HA, Omer HK. Research Article Solubility Enhancement of a Poorly Water-Soluble Drug Using Hydrotropy and Mixed Hydrotropy-Based Solid Dispersion Techniques.
Mankar SD, Rachh PR. Formulation, Development, Evaluation and Solubility Enhancement of Lercanidipine Hydrochloride by Inclusion Complex Method. NVEO-NATURAL VOLATILES & ESSENTIAL OILS Journal| NVEO. 2021 Nov 15:3862-85
Singh Y., Meher J. G., Raval K., et al. Nanoemulsion: concepts, development and applications in drug delivery. Journal of Controlled Release. 2017;252:28–49. doi: 10.1016/j.jconrel.2017.03.008.
Smith, J., & Brown, A. (2021). Recent Advances in the Development of Porous Pharmaceutical Tablets. Journal of Controlled Release, 333, 123–134. [DOI:10.1016/j.jconrel.2021.01.012]
Jain P. et al “Solubility enhancement techniques with special emphasis on hydro trophy” IJPPR vol-1 page no.34-45
R.H. Muller, B. H. L. Bohm, and J. Grau, “Nanosuspensions: a formulation approach for poorly soluble and poorly bioavailable drugs,” in Handbook of Pharmaceutical Controlled Release Technology, D. Wise, Ed., pp. 345–357, 200
Porter, C. J. H., Trevaskis, N. L., & Charman, W. N. (2007). Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Advanced Drug Delivery Reviews, 59(7), 625-638.
Stella, V. J., & Nti-Addae, K. W. (2007). Prodrug strategies to overcome poor water solubility. Advanced Drug Delivery Reviews, 59(7), 677-694.
Serajuddin, A. T. M. (2007). Salt formation to improve drug solubility. Advanced Drug Delivery Reviews, 59(7), 603-616.
Albetawi S, Abdalhafez A, Abu-Zaid A, Matrouk A, Alhourani N. Recent solubility and dissolution enhancement techniques for repaglinide a BCS class II drug: A review. Pharmacia. 2021 Apr8;68(3):573-83.
Semalty A. Cyclodextrin and phospholipid complexation in solubility and dissolution enhancement: a critical and meta-analysis. Expert opinion on drug delivery. 2014 Aug 1;11(8):1255-72.
Lankalapalli S, Beeraka NM, Bulusu BT. Studies on oral bioavailability enhancement of Itraconazole salts by complexation with Sulfo-butyl7 ether β cyclodextrin. IJRPC. 2018;8(1):131-43.
Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., & Savolainen, J. (2008). Prodrugs: Design and clinical applications. Nature Reviews Drug Discovery, 7(3), 255-270.
Stella, V. J., & Nti-Addae, K. W. (2007). Prodrug strategies to overcome poor water solubility. Advanced Drug Delivery Reviews, 59(7), 677-694.
Huttunen, K. M., Raunio, H., & Rautio, J. (2011). Prodrugs—from serendipity to rational design. Pharmacological Reviews, 63(3), 750-771 Drug development and industrial pharmacy. 2014 Sep 1;40(9):1199-205.
A Review" (Research Journal of Pharmacy and Technology, 2009) Provides foundational insights into how the BCS classifies drugs based on solubility and permeability and its role in guiding formulation development. RJPT Online.
Emerging Role of Biopharmaceutical Classification and … (PMC review article) Explores the scientific basis of the BCS, such as dissolution, permeability, regulatory relevance, and the system’s application in streamlining bioequivalence studies.
The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines Author links open overlay panel Aggelos Charalabidis , Maria Sfouni Christel Bergström c, Panos. Macheras.
Drug Permeability: Best Practices for Biopharmaceutics Classification System Based Biowaivers December 6, 2021
The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC Yasuhiro Tsume a, Deanna M Mudie a, Peter Langguth b, Greg E Amidon a, Gordon L Amidon a,
CaliciBoost” Model for Caco-2 Permeability Prediction (2025) Introduces an AutoML-based approach that significantly enhances the accuracy of Caco-2 permeability predictions, aiding early-stage drug screening and more reliable classification under BCS.
Hybrid Neural Network–Mechanistic Model for PK Prediction (2023) Demonstrates improved prediction of systemic availability using a combined neural network and mechanistic modeling approach, bridging machine learning with pharmacokinetic insight.Demonstrates improved prediction of systemic availability using a combined neural network and mechanistic modeling approach, bridging machine learning with pharmacokinetic insight.
Reference
Amidon GL, Lennernäs H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413-420.
Reddy BBK, Karunakar A. Biopharmaceutics classification system: a regulatory approach. Dissolution Technol. 2011;18:31-37
Emami J, “In vitro - in vivo correlation: From theory to applications,” J. Pharm. Pharmaceut. Sci., 2006; 9(2): 169-189
Kumar R, Thakur AK, Chaudhari P, Banerjee N. Particle size reduction techniques of pharmaceutical compounds for the enhancement of their dissolution rate and bioavailability. Journal of Pharmaceutical Innovation. 2022 Jun;17(2):333-52.
Martena V, Shegokar R, Di Martino P, Müller RH. Effect of four different size reduction methods on the particle size, solubility enhancement and physical stability of nicergoline nanocrystals.
Kunam VI, Garikapati DR, Suryadevara VI, Mandava VB, Janga RB, Sunkara SP. Solubility and dissolution rate enhancement of telmisartan by solid dispersion and pelletization techniques using soluplus as carrier. International Journal of Applied Pharmaceutics. 2020;12(1):50-8
Ali HA, Omer HK. Research Article Solubility Enhancement of a Poorly Water-Soluble Drug Using Hydrotropy and Mixed Hydrotropy-Based Solid Dispersion Techniques.
Mankar SD, Rachh PR. Formulation, Development, Evaluation and Solubility Enhancement of Lercanidipine Hydrochloride by Inclusion Complex Method. NVEO-NATURAL VOLATILES & ESSENTIAL OILS Journal| NVEO. 2021 Nov 15:3862-85
Singh Y., Meher J. G., Raval K., et al. Nanoemulsion: concepts, development and applications in drug delivery. Journal of Controlled Release. 2017;252:28–49. doi: 10.1016/j.jconrel.2017.03.008.
Smith, J., & Brown, A. (2021). Recent Advances in the Development of Porous Pharmaceutical Tablets. Journal of Controlled Release, 333, 123–134. [DOI:10.1016/j.jconrel.2021.01.012]
Jain P. et al “Solubility enhancement techniques with special emphasis on hydro trophy” IJPPR vol-1 page no.34-45
R.H. Muller, B. H. L. Bohm, and J. Grau, “Nanosuspensions: a formulation approach for poorly soluble and poorly bioavailable drugs,” in Handbook of Pharmaceutical Controlled Release Technology, D. Wise, Ed., pp. 345–357, 200
Porter, C. J. H., Trevaskis, N. L., & Charman, W. N. (2007). Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Advanced Drug Delivery Reviews, 59(7), 625-638.
Stella, V. J., & Nti-Addae, K. W. (2007). Prodrug strategies to overcome poor water solubility. Advanced Drug Delivery Reviews, 59(7), 677-694.
Serajuddin, A. T. M. (2007). Salt formation to improve drug solubility. Advanced Drug Delivery Reviews, 59(7), 603-616.
Albetawi S, Abdalhafez A, Abu-Zaid A, Matrouk A, Alhourani N. Recent solubility and dissolution enhancement techniques for repaglinide a BCS class II drug: A review. Pharmacia. 2021 Apr8;68(3):573-83.
Semalty A. Cyclodextrin and phospholipid complexation in solubility and dissolution enhancement: a critical and meta-analysis. Expert opinion on drug delivery. 2014 Aug 1;11(8):1255-72.
Lankalapalli S, Beeraka NM, Bulusu BT. Studies on oral bioavailability enhancement of Itraconazole salts by complexation with Sulfo-butyl7 ether β cyclodextrin. IJRPC. 2018;8(1):131-43.
Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D., Järvinen, T., & Savolainen, J. (2008). Prodrugs: Design and clinical applications. Nature Reviews Drug Discovery, 7(3), 255-270.
Stella, V. J., & Nti-Addae, K. W. (2007). Prodrug strategies to overcome poor water solubility. Advanced Drug Delivery Reviews, 59(7), 677-694.
Huttunen, K. M., Raunio, H., & Rautio, J. (2011). Prodrugs—from serendipity to rational design. Pharmacological Reviews, 63(3), 750-771 Drug development and industrial pharmacy. 2014 Sep 1;40(9):1199-205.
A Review" (Research Journal of Pharmacy and Technology, 2009) Provides foundational insights into how the BCS classifies drugs based on solubility and permeability and its role in guiding formulation development. RJPT Online.
Emerging Role of Biopharmaceutical Classification and … (PMC review article) Explores the scientific basis of the BCS, such as dissolution, permeability, regulatory relevance, and the system’s application in streamlining bioequivalence studies.
The Biopharmaceutics Classification System (BCS) and the Biopharmaceutics Drug Disposition Classification System (BDDCS): Beyond guidelines Author links open overlay panel Aggelos Charalabidis , Maria Sfouni Christel Bergström c, Panos. Macheras.
Drug Permeability: Best Practices for Biopharmaceutics Classification System Based Biowaivers December 6, 2021
The Biopharmaceutics Classification System: Subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC Yasuhiro Tsume a, Deanna M Mudie a, Peter Langguth b, Greg E Amidon a, Gordon L Amidon a,
CaliciBoost” Model for Caco-2 Permeability Prediction (2025) Introduces an AutoML-based approach that significantly enhances the accuracy of Caco-2 permeability predictions, aiding early-stage drug screening and more reliable classification under BCS.
Hybrid Neural Network–Mechanistic Model for PK Prediction (2023) Demonstrates improved prediction of systemic availability using a combined neural network and mechanistic modeling approach, bridging machine learning with pharmacokinetic insight.Demonstrates improved prediction of systemic availability using a combined neural network and mechanistic modeling approach, bridging machine learning with pharmacokinetic insight.
10.5281/zenodo.19903865
